Cullen/Frost Bankers’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$229K Buy
2,270
+1,195
+111% +$124K ﹤0.01% 556
2026
Q1
$104K Buy
1,075
+1,060
+7,067% +$109K ﹤0.01% 664
2025
Q4
$1.59K Buy
+15
New +$1.74K ﹤0.01% 1275
2025
Q3
Sell
-18
Closed -$2.22K 1368
2025
Q2
$2.22K Sell
18
-12
-40% -$1.37K ﹤0.01% 1169
2025
Q1
$3.04K Buy
30
+14
+88% +$1.37K ﹤0.01% 1113
2024
Q4
$1.48K Buy
+16
New +$1.57K ﹤0.01% 1191
2023
Q2
Sell
-400
Closed -$21.6K 1168
2023
Q1
$21.6K Hold
400
﹤0.01% 854
2022
Q4
$23.9K Hold
400
﹤0.01% 814
2022
Q3
$18K Sell
400
-103
-20% -$5.15K ﹤0.01% 869
2022
Q2
$22K Sell
503
-5
-1% -$257 ﹤0.01% 821
2022
Q1
$29K Hold
508
﹤0.01% 827
2021
Q4
$26K Buy
508
+5
+1% +$258 ﹤0.01% 862
2021
Q3
$30K Hold
503
﹤0.01% 889
2021
Q2
$31K Hold
503
﹤0.01% 890
2021
Q1
$33K Hold
503
﹤0.01% 791
2020
Q4
$33K Hold
503
﹤0.01% 772
2020
Q3
$26K Hold
503
﹤0.01% 781
2020
Q2
$25K Hold
503
﹤0.01% 771
2020
Q1
$26K Hold
503
﹤0.01% 595
2019
Q4
$28K Buy
+503
New +$27.3K ﹤0.01% 723

Other funds holding EHC

Cullen/Frost Bankers's EHC Position: Q2 2026 in Review

Cullen/Frost Bankers increased its Encompass Health (EHC) stake by 111% in Q2 2026, buying an estimated $124K and bringing the position to 2,270 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #556.

Cullen/Frost Bankers first reported a position in EHC in Q4 2019 and has held it in 20 quarters since. 290 funds tracked by Wall St. Rank hold EHC as of Q2 2026.

  • Cullen/Frost Bankers held 2,270 shares of Encompass Health worth $229K as of Q2 2026.
  • Cullen/Frost Bankers bought 1,195 Encompass Health shares in Q2 2026, an estimated $124K.
  • Encompass Health made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #556 holding.
  • Cullen/Frost Bankers first reported a position in Encompass Health in Q4 2019 and has held it in 20 quarters since.
  • 290 funds tracked by Wall St. Rank held Encompass Health as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.